| 胸腺上皮肿瘤中程序性死亡蛋白1及其配体的临床研究进展 |
| |
| 引用本文： | 王凯瑞,郭 丽,梁永峰,李 涛.胸腺上皮肿瘤中程序性死亡蛋白1及其配体的临床研究进展[J].现代肿瘤医学,2020,0(9):1580-1582. |
| |
| 作者姓名： | 王凯瑞 郭 丽 梁永峰 李 涛 |
| |
| 作者单位： | 1.宁夏医科大学研究生院，宁夏 银川 750004;2.宁夏医科大学总医院肿瘤医院肿瘤外科，宁夏 银川 750004 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81660500);国家自然科学基金（编号:81660500）；宁夏医科大学国内一流建设学科临床医学项目资助（编号:NXYLXK2017A05） |
| |
| 摘 要： | 近年来，随着免疫治疗及肿瘤微环境概念的广泛普及，许多肿瘤靶向位点被人们关注并投以大量的实验研究。程序性死亡蛋白1及其配体（PD-1/PD-L1）作为目前最热门的一个免疫靶点通路，其抑制剂已经应用于多种恶性肿瘤的治疗当中。胸腺上皮肿瘤（TETs）是一种较为少见的肿瘤，目前已有证据表明PD-L1在TETs中存在高表达水平并且其与疾病的预后相关，因此本文针对PD-1/PD-L1在TETs中的临床研究进展作一综述。
|
| 关 键 词： | 胸腺上皮肿瘤 程序性死亡蛋白1 程序性死亡蛋白1配体 免疫治疗 |
Research progression of PD-1/PD-L1 in thymic epithelial tumors |
| |
| Wang Kairui,Guo Li,Liang Yongfeng,Li Tao.Research progression of PD-1/PD-L1 in thymic epithelial tumors[J].Journal of Modern Oncology,2020,0(9):1580-1582. |
| |
| Authors: | Wang Kairui Guo Li Liang Yongfeng Li Tao |
| |
| Affiliation: | 1.Graduate School of Ningxia Medical University，Ningxia Yinchuan 750004，China；2.Department of Surgical Oncology，Tumor Hospital，General Hospital of Ningxia Medical University，Ningxia Yinchuan 750004，China. |
| |
| Abstract: | Recently，with the widespread popularity of immunotherapy and the concept of tumor microenvironment，many tumor targeting sites have attracted attention and a large number of experimental studies have been conducted.As one of the most popular tumor immune signaling pathway，inhibitor of PD-1/PD-L1 has been used in the treatment of a variety of malignant tumors.TETs is a relatively rare tumor.Currently，there are evidences that PD-L1 has a high expression level in TETs and is related to the prognosis of the disease.Therefore，the aim of this paper is to summarize the research progression of PD-1/PD-L1 in TETs. |
| |
| Keywords: | thymic epithelial tumors programmed cell death protein 1 programmed cell death ligand 1 immunotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
